Evidence map›Paper›PMID 38902365›Full record

ArticleVirchows Archiv : an international journal of pathology2025

TRPS1 expression in breast angiosarcoma.

Tamás Pancsa, Boglárka Pósfai, Anna Schubert, Szintia Almási, Eszter Papp, Yi-Che Chang Chien, Endre Kálmán, Kristóf Attila Kovács, Janina Kulka, Linda Varga and 2 more

Abstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tamás PancsaDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Boglárka PósfaiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Anna SchubertDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Szintia AlmásiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Eszter PappDepartment of Surgical and Molecular Pathology, Tumor Pathology Center, National Institute of Oncology, Budapest, Hungary.
Yi-Che Chang ChienDepartment of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Endre KálmánDepartment of Pathology, Faculty of Medicine and Clinical Center, University of Pécs, Pécs, Hungary.
Kristóf Attila KovácsDepartment of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
Janina KulkaDepartment of Pathology, Forensic and Insurance Medicine, Semmelweis University, Budapest, Hungary.
Linda VargaDepartment of Oncotherapy, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Gábor CserniDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Levente KuthiDepartment of Surgical and Molecular Pathology, Tumor Pathology Center, National Institute of Oncology, Budapest, Hungary. kuthilevente@gmail.com.ORCID http://orcid.org/0000-0001-9247-6679

Funding

Magyarország Kormánya ÚNKP-23-4-SZTE-385Szent-Györgyi Albert Orvostudományi Kar, Szegedi Tudományegyetem 5S 340 A202
6 · The paper itself

Abstract

Angiosarcoma (AS) of the breast, a rare mesenchymal neoplasm, exhibits distinct forms based on etiological and genetic features. While cases with typical clinical presentation and morphology allow for a straightforward diagnosis, challenges arise when clinical data are scarce, diagnostic material is limited, or morphological characteristics overlap with other tumors, including undifferentiated carcinomas. The trichorhinophalangeal syndrome protein 1 (TRPS1), once regarded as highly specific for breast carcinomas, now faces doubts regarding its reliability. This study explores TRPS1 expression in breast AS. Our investigation revealed that 60% of AS cases displayed TRPS1 labeling, contrasting with the 40% lacking expression. Scoring by four independent readers established a consensus, designating 12/35 ASs as unequivocally TRPS1-positive. However, uncertainty surrounded nine further cases due to a lack of reader agreement (being substantial as reflected by a kappa value of 0.76). These findings challenge the perceived specificity of TRPS1, shedding light on its presence in a noteworthy proportion of breast ASs. Consequently, the study underscores the importance of a comprehensive approach in evaluating breast ASs and expands the range of entities within the differential diagnosis associated with TRPS1 labeling.

Indexed as

Biomarkers, TumorBreast NeoplasmsDNA-Binding ProteinsHemangiosarcomaRepressor ProteinsTranscription FactorsAdultAgedAged, 80 and overDiagnosis, DifferentialFemaleHumansImmunohistochemistryMiddle AgedBiomarkers, TumorDNA-Binding ProteinsRepressor ProteinsTranscription FactorsTRPS1 protein, humanAngiosarcomaBreastImmunohistochemistryTRPS1

Identifiers

PMID38902365
PMCPMC11950113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.